Abstract
To evaluate the prognostic relevance of Ki‐67 and topoisomerase IIα expression in relation to tumor stage, grade, and hormone receptor content, 942 ductal infiltrating carcinomas of the breast were examined by means of the monoclonal antibodies Ki‐S11 (Ki‐67) and Ki‐S4 (topoisomerase IIα). pS2, c‐erbB2, and p53 were additionally considered as prognostic variables. The median follow‐up time was 149 months. Eight‐hundred‐and‐sixty‐three tumors reacted with Ki‐S11 and Ki‐S the labeling indices of the two antigens were closely associated (r=0.93). Both correlated positively with the tumor size, c‐erbB2, and p53 expression, and negatively with patient age, hormone receptor content, and pS2 immunostaining. In the univariate analysis, Ki‐S11 and Ki‐S4 scores, nodal status, tumor size, tumor grade, and progesterone receptor content strongly predicted both overall and metastasis‐free survival (p <0.00001). Estrogen receptor status, p53, and c‐erbB2 were of minor significance. Concerning overall survival, multivariate Cox regression analysis selected a Ki‐S4 score >25% (p < 0.00001) next to the nodal status, and before tumor size, progesterone receptor content, and patient age. Independent predictors of the occurrence of distant metastases were nodal status, Ki‐S4, tumor size, grade 1, and progesterone receptor negativity, in that order. The Ki‐S11 score was of independent prognostic significance only if examined as a continuous variable. We conclude that topoisomerase IIα expression as assessed by monoclonal antibody Ki‐S4 may add valuable information to current prognostic models for breast cancer. Its predictive value appears to be essentially related to the proliferative activity of tumor cells.
Similar content being viewed by others
References
Hedley DW, Rugg CA, Gelber RD: Association of DNA index and S-phase fraction with prognosis of node-positive early breast cancer. Cancer Res 47: 4729–4735, 1987
Merkel DE, Winchester DJ, Goldschmidt RA, August CZ, Wruck DM, Rademaker AW: DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph nodenegative breast cancer. Cancer 72: 1926–1932, 1993
Witzig TE, Ingle JN, Cha SS, Schaid DJ, Tabery RL, Wold LE, Grant C, Gonchoroff NJ, Katzmann JA: DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node-negative breast cancer: Cancer 74: 1752–1761, 1994
Gasparini G, Boracchi P, Verderio P, Bevilacqua P: Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57: 822–829, 1994
Stal O, Dufmats M, Hatschek T, Carstensen J, Klintenberg C, Rutqvist LE, Skoog L, Sullivan S, Wingren S, Nordenskjold B: S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 11: 1717–1722, 1993
Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le Doussal V, Tubiana-Hulin M, Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J NatI Cancer Inst 84: 1266–1272, 1992
Lipponen P, Eskelinen M, Papinaho S, Klemi PJ, Aaltomaa S, Kosma VM, Mann S, Syrjanen K: Sex steroid receptors, Sphase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer. Anticancer Res 12: 677–682, 1992
Sampson SA, Kreipe H, Gillett CE, Smith P, Chaudary MA, Khan A, Wicks K, Parwaresch R, Barnes DM: KiS1 – a novel monoclonal antibody which recognizes proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma. J Pathol 168: 179–185, 1992
Kreipe H, AIm P, Olsson H, Hauberg M, Fischer L, Parwaresch R: Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 142: 651–657, 1993
Rudas M, Gnant MF, Mittlbock M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A: Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis. Breast Cancer Res Treat 32: 165–175, 1994
Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926–3931, 1993
Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa AP, Calderini P, Liscia DS: Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: Its prognostic value on short-term recurrences. Eur J Cancer 29A: 1509–1513, 1993
Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K: The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122: 687–692, 1996
Pierga JY, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelenat H: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37: 57–64, 1996
Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Janicke F, Nathrath W, Schmitt M, Graeff H, Hofler H: Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75: 1525–1533, 1997
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984
Gerdes J, Li L, Schlüter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad H-D: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1384: 867–873, 1991
Schwarting R: Little missed markers and Ki-67. Lab Invest 68(6): 597–599, 1993
Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH: Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2: 209–214, 1991
Watanabe M, Tsutsui K, Inoue Y: Differential expressions of the topoisomerase II alpha and II beta mRNAs in developing rat brain. Neurosci Res 19: 51–57, 1994
Kellner U, Heidebrecht HJ, Rudolph P, Biersack H, Buck F, Dakowski T, Wacker HH, Domanowski M, Seidel A, Westergaard O, Parwaresch R: Detection of topoisomerase II alpha in cell lines and tissues – characterization of five novel monoclonal antibodies. J Histochem Cytochem 45: 251–263, 1997
Lynch BJ, Guinee DG Jr, Holden JA: Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer [In Process Citation]. Hum Pathol 28: 1180–1188, 1997
Wang JC: Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1–9, 1987
Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M: DNA topoisomerase is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50: 917–925, 1987
Wang JC: DNA topoisomerases as targets of therapeutics: An overview. Adv Pharmacol 29: 1–19, 1994
Rio MC, Bellocq JP, Daniel JY, Tomasetto C, Lathe R, Chenard MP, Batzenschlager A, Chambon P: Breast cancerassociated pS2 protein: Synthesis and secretion by normal stomach mucosa. Science 241: 705–708, 1988
Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, Chambon P: Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res 12: 2861–2878, 1984
Foekens JA, Rio MC, Seguin P, van Putten WL, Fauque J, Nap M, Klijn JG, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832–3837, 1990
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987
Guérin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB2 and EGF receptor genes in inflammatory and noninflammatory breast cancer: Prognostic significance. Int J Cancer 43: 201–208, 1989
Bacus SS, Zelnick CR, Plowman G, Yarden Y: Expression of the erbB2 family of growth factor receptors and their ligands in breast cancers: Implication for tumor biology and clinical behavior. Am J Clin Pathol 102: S13–S24, 1994
Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ: The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB2, Ki-67 and PCNA expression in breast cancer. Anticancer Res 16: 3141–3147, 1996
Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helm HH, Isola JJ: Association of c-erbB2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–655, 1991
Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438, 1991
Quénel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: The prognostic value of cerbB2 in primary breast carcinomas: A study of 942 cases. Breast Cancer Res Treat 35: 283–291, 1995
Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109–1114, 1992
Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55: 51–56, 1993
Silvestrini R, Benini F, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604–1610, 1996
Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ: Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis. Int J Cancer 69: 135–141, 1996
MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study of 942 cases. Breast Cancer Res Treat 36: 71–81, 1995
Rudolph P, Kellner U, Chassevent A, Collin F, Bonichon F, Parwaresch R, Coindre JM: Prognostic relevance of a novel proliferation marker, Ki-S11, for soft tissue sarcoma: A multivariate study. Am J Pathol 150: 1997–2007, 1997
Rudolph P, Heidebrecht H-J, Kellner U, Seidel A, Parwaresch MR: Proliferation marker Ki-S1 binds to a formalin-resistant epitope of topoisomerase II. Int J Surg Pathol 2: 388, 1995 (Abstract)
Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H: Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha: Delineation of a carboxyterminal epitope with peptide antibodies. Am J Pathol 146: 1302–1308, 1995
de Mascarel I, Soubeyran I, MacGrogan G, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM: Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Appl Immunohistochem: 3: 222–231, 1995
MacGrogan G, Soubeyran I, de Mascarel I, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM: Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas: A correlative study of 942 cases. Appl Immunohistochem 4: 219–227, 1996
Soubeyran I, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Immunohistochemical determination of pS2 in invasive breast carcinomas: A study of 942 cases. Breast Cancer Res Treat 34: 119–128,1995
Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JR: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66: 970–976, 1992
Kreipe H, Heidebrecht HJ, Hansen S, Rohlk W, Kubbies M, Wacker HH, Tiemann M, Radzun HJ, Parwaresch R: A new proliferation-associated nuclear antigen detectable in paraffinembedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 142: 3–9, 1993
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M: c-erbB2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N EngI J Med 330: 1260–1266, 1994
Ravdin PM, Chamness GC: The c-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers – a review. Gene 159: 19–27, 1995
Soubeyran I, Quénel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: A marker improving prediction of response to neoadjuvant tamoxifen in postmenopausal breast cancer patients. Br J Cancer 74: 1120–1125, 1996
Levine AJ: The p53 tumor suppressor gene (editorial). N EngI J Med 326: 1350–1352, 1992
Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299, 1997
Eder JP Jr, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA, Schnipper LE: DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res 55: 6109–6116, 1995
Järvinen TAH, Kononen J, Pelto-Huikko M, Isola J: Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148: 2073–2082, 1996
Rudolph P, Knüchel R, Endl E, Heidebrecht HJ, Hofstädter F, Parwaresch R: The immunohistochemical marker Ki-S2: Tissue distribution and cell cycle kinetics of a novel proliferationspecific antigen. Mod Pathol 1998 (In Press)
Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 73: 1518–1524, 1996
Sulkes A, Livingston RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62: 513–515, 1979
Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383–1387, 1989
O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA: DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 28: 681–683, 1992
Hietanen P, Blomqvist C, Wasenius VM, Niskanen E, Franssila K, Nordling S: Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 71: 1029–1032, 1995
MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB2, MiB1, pS2 and GSTpi. Br J Cancer 74: 1458–1465, 1996
Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Giunchi DC, Vio A, Saragoni A, Silvestrini R: Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study. Breast Cancer Res Treat 43: 7–14, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rudolph, P., MacGrogan, G., Bonichon, F. et al. Prognostic significance of Ki‐67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast. Breast Cancer Res Treat 55, 61–71 (1999). https://doi.org/10.1023/A:1006159016703
Issue Date:
DOI: https://doi.org/10.1023/A:1006159016703